TP53 and central nervous system cancer: Additionally, the IDH-driven epigenetic changes remain the glioma cells in a less differentiated or stem-like state, rendering them vulnerable to suffering additional oncologic events, such as the mutation of tumor suppressor protein 53 (TP53) [23].